Tagged with S

Korea Research Institute of Bioscience and Bi Though you have recently been appointed as President of KRIBB, your history with the institute goes quite far back. Could you please briefly explain the role it plays within South Korea’s bioscience and biotech fields? The KRIBB is the only government-supported research institute in South Korea dedicated to the field…

Cegedim Dendrite South Korea You have been working in the CRM industry, particularly with pharmaceutical companies, for more then 10 years. Could you briefly introduce to our readers how the CRM industry has evolved in South Korea throughout this period? I understand that ETMS (Electronic Territory Management System) was introduced to Korea in late…

IMS Health Italy You have worked in other countries such as the UK and the US with very large and significant pharmaceutical industries. What would you say is particular about the Italian pharmaceutical market? The Italian situation is changing a lot, at a different speed than in other countries. For years, Italians had…

Novartis South Korea Novartis’ Head Office in Basel, Switzerland as well as several prior international assignments in Asia and Europe. What do you find as the most interesting particularities of the pharmaceutical sector in the country thus far? Korea is a great country to work. Having only been here for a limited amount…

Solvay Pharma Indonesia While the level of sales for pharmaceutical products is plunging in the US and Europe one of the core pillar of Solvay’s strategy is to have a stronger focus on the Asia Pacific region, which for the Pharmaceutical segment represents still less than 9% of the sales. In this respects,…

Shin Poong Pharm Could you please introduce Shinpoong, which you founded in 1962, and mention the main milestones of this unique company in the Korean pharmaceutical industry? I founded Shinpoong in a very delicate and decisive time for Korea. During the civil war the population had to face serious epidemics, and by the…

Minister for Health How would you rate South Korea’s healthcare system when compared to regional peers and other OECD countries – main strong points and room for improvement? Since the introduction of the national health insurance system in 1977, the Korean national healthcare system has been experiencing dramatic growth, guaranteeing healthcare to every…

Assobiotec Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report dedicated to biotechnologies in Italy, the sector’s turnover reaches approximately 5 billion Euros and represents 0,6% of the global Italian…

GSK Germany You have been leading GSK, one of the top five pharmaceutical companies in the German market, for just over a year, after having worked previously in Poland, the UK, France, U.S.A. and Ireland. What has your 20 year career in the pharmaceutical sector taught you about successful management in such…

generics “The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make hard decisions.” Until now, generics prescriptions were limited by strong links between innovators and doctors, and price alignment trends reducing…

Russia   When the Russian Federation emerged from the former USSR in 1991 all the structures of the past social net that provided for the complete healthcare needs of citizens were just a memory of the past – nothing was left when the centralized distribution of medication of the former USSR…

Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in Russia. Prepared in association with Lidings, a leading global law firm, this is an extract from The Pharma Legal Handbook: Russia, available to purchase here for GBP 99.     1. What is the definition of Rare Diseases…